Palbociclib: all 236 studies that test it
Page 2 of 3. Open to participants first (41), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver CancerCompletedNCT01356628Phase 2Results posted
- Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.CompletedNCT01291017Phase 2Results posted
- A Study of PD 0332991 in Patients With Recurrent Rb Positive GlioblastomaTerminatedNCT01227434Phase 2Results posted
- PD0332991 (Palbociclib) in Patients With Advanced or Metastatic LiposarcomaCompletedNCT01209598Phase 2Results posted
- Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With CancerCompletedNCT01037790Phase 2Results posted
- Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerCompletedNCT00721409Phase 2Results posted
- An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2Results posted
- An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.CompletedNCT00420056Phase 1Results posted
- A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced CancerCompletedNCT00141297Phase 1Results posted
- Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in EgyptCompletedNCT07487129Phase 4
- Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell CarcinomasActive, not recruitingNCT06654297Phase 1
- ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast CancerCompletedNCT06570031Phase 1
- Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mgCompletedNCT06331715Phase 4
- Phase IV Multi-arm Study of CDK4/6 Pharmacokinetics in Healthy Volunteers With Known CYP3A4*22 GenotypeWithdrawnNCT05691400Phase 4
- TAS-116 Plus Palbociclib in Breast and Rb-null CancerWithdrawnNCT05655598Phase 1
- Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingNCT05501886Phase 3
- A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)Active, not recruitingNCT05468697Phase 1/2
- Phase II Safety Single-arm Study of CDK4/6 Inhibition With Palbociclib in Hospitalized, Moderate COVID-19 Cases to Prevent ThromboinflammationWithdrawnNCT05371275Phase 2
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsActive, not recruitingNCT05266105Phase 1
- Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) StudiesActive, not recruitingNCT05226871Phase 2
- Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)CompletedNCT05178888Phase 1
- Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
- Neoadjuvant With Trastuzumab, Pyrotinib Plus Palbociclib and Fulvestrant in HER2-positive, ER-positive Breast CancerStatus unknownNCT05076695Phase 2
- Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine TherapyActive, not recruitingNCT05069038Phase 2
- Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic LeukemiaCompletedNCT04996160Phase 1
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2
- A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast CancerWithdrawnNCT04872608Phase 1
- Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic CancerWithdrawnNCT04870034Early Phase 1
- Tumor Response Time of Palbociclib in Combination With AI in Real-world Chinese PatientsStatus unknownNCT04858997Phase 2
- Study of CYH33 in Combination With Endocrine Therapy With or Without Palbociclib in Patients With HR+, HER2- Advanced Breast CancerStatus unknownNCT04856371Phase 1
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingNCT04841148Phase 2
- AZD9833 China PK StudyCompletedNCT04818632Phase 1
- Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
- ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)Status unknownNCT04669587Phase 1/2
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
- Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain MetastasesWithdrawnNCT04585724Phase 1
- DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)Active, not recruitingNCT04567420Phase 2
- PF-07104091 as a Single Agent and in Combination TherapyActive, not recruitingNCT04553133Phase 2
- Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerWithdrawnNCT04498520Phase 1
- Palbociclib and INCMGA00012 in People With Advanced LiposarcomaActive, not recruitingNCT04438824Phase 2
- PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerActive, not recruitingNCT04360941Phase 1
- Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2
- Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal TherapyStatus unknownNCT04318223Phase 2
- High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)Status unknownNCT04247633Phase 2
- Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant ChemotherapyCompletedNCT04130152Early Phase 1
- Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast CancerCompletedNCT03969121Phase 3
- Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian CancerCompletedNCT03936270Phase 2
- Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerActive, not recruitingNCT03900884Phase 1
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsActive, not recruitingNCT03870919Not applicable
- Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast CancerActive, not recruitingNCT03820830Phase 3
- PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA)CompletedNCT03809988Phase 2
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedNCT03784014Phase 3
- The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast CancerStatus unknownNCT03756090Not applicable
- Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerTerminatedNCT03709082Phase 1/2
- HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerCompletedNCT03685331Phase 1
- Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast CancerCompletedNCT03628066Phase 2
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1
- Adjuvant Palbociclib in Elderly Patients With Breast CancerActive, not recruitingNCT03609047Phase 2
- Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast CancerActive, not recruitingNCT03573648Phase 2
- A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast CancerStatus unknownNCT03560856Phase 2
- Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic LeukemiaTerminatedNCT03515200Phase 1
- Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03498378Phase 1
- Phase II Palbociclib +Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT03478514Phase 2
- Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaCompletedNCT03472573Phase 1
- A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast CancerCompletedNCT03471663Phase 1
- G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerCompletedNCT03455270Phase 1
- Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene AberrationsStatus unknownNCT03454919Phase 2
- Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to FulvestrantCompletedNCT03447132Phase 3
- PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studYActive, not recruitingNCT03423199Phase 3
- A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).CompletedNCT03355157Phase 4
- A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast CancerActive, not recruitingNCT03332797Phase 1
- HR+/HER2- Advanced Breast Cancer and Endocrine ResistanceTerminatedNCT03322215Phase 2
- Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic BreastActive, not recruitingNCT03304080Phase 1/2
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
- Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of PalbociclibCompletedNCT03220191Phase 1
- Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine TherapyTerminatedNCT03220178Phase 4
- A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial TumorStatus unknownNCT03219554Phase 2
- Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBCCompletedNCT03184090Phase 2
- Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerCompletedNCT03170206Phase 1
- NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
- Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast CancerTerminatedNCT03128619Phase 1
- Histology-Independent Study of Palbociclib in Patients With Advanced CancerWithdrawnNCT03123744Phase 2
- CDK4/6 Inhibition in Locally Advanced/Metastatic ChordomaCompletedNCT03110744Phase 2
- Biomarker-based Study in R/M SCCHNActive, not recruitingNCT03088059Phase 2
- Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)CompletedNCT03065621Phase 2
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedNCT03065387Phase 1
- Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsSuspendedNCT03065062Phase 1
- Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell CarcinomaActive, not recruitingNCT03024489Phase 1/2
- Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast CancerActive, not recruitingNCT02942355Phase 2
- PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast CancerStatus unknownNCT02917005Phase 2
- Palbociclib in Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT02905318Phase 2
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2
- A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)CompletedNCT02806648Phase 2
- Palbociclib and FES PETCompletedNCT02806050Phase 2
- Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by SurgeryCompletedNCT02760030Phase 2
- Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase InhibitorActive, not recruitingNCT02738866Phase 2